Literature DB >> 26516962

Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.

Guilherme Henrique Furtado1, Leandro Cardinal1, Rodrigo Spineli Macedo1, Juliana Oliveira Silva1, Eduardo Alexandrino Medeiros1, Joseph Levente Kuti2, David Paul Nicolau2.   

Abstract

INTRODUCTION: Monte Carlo simulations have been used for selecting optimal antibiotic regimens for treatment of bacterial infections. The aim of this study was to assess the pharmacokinetic and pharmacodynamic target attainment of intravenous β-lactam regimens commonly used to treat bloodstream infections (BSIs) caused by Gram-negative rod-shaped organisms in a Brazilian teaching hospital.
METHODS: In total, 5,000 patients were included in the Monte Carlo simulations of distinct antimicrobial regimens to estimate the likelihood of achieving free drug concentrations above the minimum inhibitory concentration (MIC; fT > MIC) for the requisite periods to clear distinct target organisms. Microbiological data were obtained from blood culture isolates harvested in our hospital from 2008 to 2010.
RESULTS: In total, 614 bacterial isolates, including Escherichia coli, Enterobacterspp., Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa, were analyzed Piperacillin/tazobactam failed to achieve a cumulative fraction of response (CFR) > 90% for any of the isolates. While standard dosing (short infusion) of β-lactams achieved target attainment for BSIs caused by E. coliand Enterobacterspp., pharmacodynamic target attainment against K. pneumoniaeisolates was only achieved with ceftazidime and meropenem (prolonged infusion). Lastly, only prolonged infusion of high-dose meropenem approached an ideal CFR against P. aeruginosa; however, no antimicrobial regimen achieved an ideal CFR against A. baumannii.
CONCLUSIONS: These data reinforce the use of prolonged infusions of high-dose β-lactam antimicrobials as a reasonable strategy for the treatment of BSIs caused by multidrug resistant Gram-negative bacteria in Brazil.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26516962     DOI: 10.1590/0037-8682-0122-2015

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  1 in total

1.  New Supramolecular Drug Carriers: The Study of Organogel Conjugated Gold Nanoparticles.

Authors:  Joanna Kowalczuk; Andrzej Łapiński; Elżbieta Stolarczyk; Oleg M Demchuk; Konrad Kubiński; Monika Janeczko; Aleksandra Martyna; Maciej Masłyk; Sylwia Turczyniak-Surdacka
Journal:  Molecules       Date:  2021-12-09       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.